An exosome is a tiny bubble-like particle, roughly 40 to 160 nanometers in diameter, that your cells release to communicate with other cells. For scale, the average exosome is about 100 nanometers across, or roughly a thousand times smaller than the width of a human hair. Every cell in your body produces exosomes, packaging them with proteins, genetic material, fats, and other molecules that can influence the behavior of cells elsewhere in the body.
Exosomes belong to a broader family called extracellular vesicles. They’ve become one of the most studied topics in biology over the past decade because of their roles in everything from immune responses to cancer spread, and their potential as diagnostic tools and drug delivery vehicles.
How Exosomes Form Inside Cells
Exosomes don’t simply pinch off from the cell’s outer surface. They form through a more complex internal process. First, a cell’s outer membrane folds inward to create a small internal compartment. This compartment matures into a structure called a multivesicular body, essentially a larger bubble filled with many smaller bubbles inside it. The cell sorts specific cargo (proteins, bits of genetic code, fats) into these smaller internal bubbles as they form.
Once the multivesicular body is fully loaded, the cell has two options: destroy it by merging it with its recycling system (lysosomes), or send the contents out. When the multivesicular body fuses with the cell’s outer membrane, it releases those smaller internal bubbles into the space outside the cell. Those released bubbles are exosomes. The whole process is tightly regulated, with the cell controlling what gets packaged and when the cargo gets sent.
What Exosomes Carry
The contents of an exosome reflect the cell that made it. In general, exosomes carry three main categories of molecular cargo:
- Proteins: These include surface markers (CD9, CD63, and CD81 are the most commonly used to identify exosomes), structural proteins, enzymes, and immune-signaling molecules.
- Genetic material: Messenger RNA, microRNA, long non-coding RNA, and even fragments of DNA. These can alter gene activity in the cells that receive them.
- Lipids: Cholesterol, ceramides, and various phospholipids make up the exosome’s outer shell and also play roles in signaling.
This cargo isn’t random. Cells actively select what goes into exosomes, which means the contents change depending on the cell type, its current state, and whether it’s healthy or diseased. A tumor cell, for example, packages different molecules into its exosomes than a healthy cell would.
How Exosomes Communicate Between Cells
Exosomes function like molecular mail. Once released, they travel through body fluids (blood, saliva, urine, cerebrospinal fluid) and deliver their contents to recipient cells nearby or in distant tissues. Recipient cells can take up exosomes in several ways: the exosome can bind to the cell surface and trigger a signal from the outside, fuse directly with the cell membrane and dump its contents inside, or get swallowed whole through a process similar to how immune cells engulf bacteria.
This system lets cells influence each other without direct contact. Immune cells use exosomes to coordinate responses to infection. Stem cells release exosomes that promote tissue repair. Cancer cells exploit the system to prepare distant tissues for metastasis, essentially sending advance signals that make new locations more hospitable for tumor growth.
How Exosomes Differ From Other Vesicles
Cells release several types of extracellular vesicles, and exosomes are the smallest. Microvesicles are larger, typically 150 to 1,000 nanometers, and form differently. Instead of going through the internal multivesicular body pathway, they bud directly off the cell’s outer membrane. Apoptotic bodies are larger still, ranging from 1,000 to 5,000 nanometers, and form when a dying cell breaks apart during programmed cell death.
In practice, distinguishing these vesicle types in a lab sample is difficult because their sizes overlap and they share some molecular markers. Researchers generally classify small extracellular vesicles as those under 200 nanometers and large ones as those above. Exosomes are identified partly by their size, partly by their endosomal origin, and partly by the presence of specific surface markers like CD63, CD9, and CD81.
Exosomes in Cancer Diagnosis
One of the most promising applications for exosomes is in liquid biopsies, a way to detect cancer from a simple blood or urine sample instead of cutting out tissue. Because tumor cells shed exosomes into body fluids, and those exosomes carry tumor-specific proteins and genetic fragments, analyzing them can reveal what’s happening inside a tumor without an invasive procedure.
The most advanced example is a urine test called ExoDx Prostate IntelliScore, which received FDA Breakthrough Device Designation in 2019. It measures RNA levels from three genes found in urinary exosomes to estimate the likelihood of high-grade prostate cancer. Researchers are also developing exosome-based detection methods for lung cancer, pancreatic cancer, gastric cancer, bladder cancer, and liver cancer. In early-stage breast cancer, detecting a specific microRNA in exosomes identified estrogen receptor-positive tumors with 85% accuracy. For bladder cancer, a panel of three RNA molecules found in urinary exosomes outperformed traditional urine cytology, with a diagnostic accuracy score of 0.813 compared to 0.619.
The appeal of exosome-based diagnostics is their accessibility. Exosomes are abundant in blood and urine, they’re stable enough to survive collection and transport, and they carry molecular signatures that reflect their tissue of origin.
Therapeutic and Drug Delivery Potential
Because exosomes naturally deliver molecular cargo to specific cells, researchers are investigating whether they can be loaded with drugs and used as delivery vehicles. The idea is to harness the body’s own communication system to get medications exactly where they’re needed, potentially reducing side effects compared to conventional drug delivery.
Exosome-based delivery is being explored for chemotherapy, gene therapy, and other targeted treatments. Their small size allows them to cross biological barriers that block larger particles, including potentially the blood-brain barrier. They’re also less likely to trigger immune rejection than synthetic nanoparticles because they’re made of the same biological material as the body’s own cells. None of these approaches have received regulatory approval yet, but the field is active.
Exosomes in Skincare
Exosomes have become a buzzword in aesthetic medicine. Topical exosome products, often derived from stem cells, are marketed for skin rejuvenation. A systematic review of human studies found that exosome-based treatments were associated with short-term improvements in skin hydration, elasticity, wrinkle depth, pore size, pigmentation, and overall texture over follow-up periods of 2 to 12 weeks. When applied topically alongside microneedling or energy-based devices like radiofrequency, the treatments showed good tolerability, with only mild, temporary local reactions reported.
The caveats are significant. Study sizes have been small, follow-up periods short, and there’s a lack of standardization across products. Split-face comparisons suggested that topical exosome treatments performed similarly to platelet-rich plasma after microneedling, but formal statistical analysis was limited. The evidence is encouraging but early.
Regulatory Status and Safety Concerns
No exosome products are currently approved by the FDA. The agency classifies exosomes used to treat diseases as drugs and biological products, meaning they must go through the standard premarket review and approval process. In 2019, the FDA issued a public safety notification after patients in Nebraska experienced serious adverse events from unapproved exosome products administered by injection at clinics. The agency specifically warned that clinics offering these products outside of the FDA review process are operating without regulatory oversight.
This distinction matters if you encounter exosome treatments at a clinic or medical spa. Topical exosome preparations used alongside standard aesthetic procedures have shown a generally positive safety profile in controlled clinical settings. Injectable exosome products, on the other hand, carry risks that haven’t been fully evaluated through clinical trials. The gap between the science and what’s currently available commercially is wide, and the regulatory framework is still catching up.